As of 27 April 2015, the company Biocartis is listed in Brussels. To celebrate this event, CEO and founder, Rudi Pauwels, opened the markets with a Bell Ceremony. Hilde Windels, CFO and general manager, had the honor to write the first opening price on the blackboard.
Biocartis raised €100M in an oversubscribed successful IPO on Euronext Brussels. The reference price was fixed at €11.50. Market cap amounts to €450.2M on the day of its introduction.
The IPO of Biocartis on Euronext Brussels is the largest Life Sciences transaction this year on the European markets, and ranks amongst the 10 largest IPO’s the last 10 years on Euronext Brussels.
Biocartis specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
The ticker code is : BCART
If you would like to find out more : www.biocartis.com